Results 111 to 120 of about 9,329 (213)

Tautomerism and non-covalent interactions of flucytosine with armchair (5,5) SWCNT and γ-Fe₂O₃ nanoparticles: A DFT study

, 2017
626-632The structural parameters, energetic behavior and natural bond orbital analysis of flucytosine, as well as its tautomerization mechanism are explored theoretically using density functional theory calculations.
Beyramabadi, S Ali, Pordel, Mehdi, Mohammad-Hasani, Elham   +2 more
core  

Urosepsis by multidrug-resistant <i>Nakaseomyces glabratus</i> with non-functional Erg3 and Erg11-do collateral sensitivity and a unique mode of action make nitroxoline a viable UTI antifungal? [PDF]

mBio
Carolus H, Biriukov V, Vreys J, Lobo Romero C, Herrera Avila JP, Vergauwen R, Sofras D, Nysten J, Vanreppelen G, Vinken L, Britto Xavier B, Gabaldón T, Lagrou K, Naesens R, Van Dijck P.   +14 more
europepmc   +1 more source

Comparative risk of arrhythmias associated with systemic antifungal agents: a disproportionality analysis of the FAERS database. [PDF]

Front Pharmacol
Yang X, Li H, Liu K, Kong L.
europepmc   +1 more source

Vibrational spectra and normal coordinate analysis of flucytosine

, 2006
581-586 A normal coordinate analysis on flucytosine has been carried out with a systematic set of symmetry coordinates following Wilson’s F-G matrix method.
Seshadri, S, Gunasekaran, S, Muthu, S
core  

Shifting Epidemiology and Antifungal Susceptibility Patterns of Clinical Fungal Isolates in an Intensive Care Unit (ICU) from Bucharest, Romania: A Retrospective Observational Study. [PDF]

Antibiotics (Basel)
Solomon MP, Mahler B, Popescu O, Ditu LM, Gheorghe-Barbu I, Chivu LI, Manolescu LSC.   +6 more
europepmc   +1 more source

Data Files for Quantum Mechanical Simulations of Cytosine and Flucytosine using ORCA

<p>This entry includes input and output files for performing quantum mechanical simulations of cytosine and flucytosine using HF, DFT and MP2 methods with different basiss sets using ORCA. </p ...
Kucukkal, Tugba, Monsurat, Lawal
core   +1 more source

Cryptococcal Osteomyelitis in a Virally Suppressed Adolescent Living With HIV: A Case Report. [PDF]

Case Rep Infect Dis
Mandikiyana Chirimuta LA, Rambanapasi C, Musorowegomo D, Nyatanga G, Mapfumo A, Chikati EF.   +5 more
europepmc   +1 more source

Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial. [PDF]

Clin Infect Dis
Rutakingirwa MK, Skipper CP, Dai B, Wele A, Namombwe S, Mugabi T, Ndyetukira JF, Sadiq A, Kabahubya M, Chemusto L, Ahimbisibwe C, Nabbale S, Kandole TK, Muyise RCB, Kagimu E, Luggya T, Mulungi J, Jjunju S, Nicol MR, Stott KE, Kwizera R, Meya DB, Boulware DR, McHale TC, FLOOR trial team .   +24 more
europepmc   +1 more source

SAHCS Guideline for the prevention, diagnosis and management of cryptococcal disease among persons living with HIV: Update to induction treatment for cryptococcal meningitis. [PDF]

South Afr J HIV Med
Govender NP, Meintjes G, Falconer J, Murphy K, Nel J, Rabie H, Frigati L, Reddy DL, Dawood H, Variava E, Potgieter S, Boyles T, Stacey SL, Mangena P, Madua MC, Wattrus C, Moosa MS.   +16 more
europepmc   +1 more source

In vitro evidence to support amphotericin B and flucytosine combination therapy for talaromycosis. [PDF]

PLoS Negl Trop Dis
Natesan Sambath H, Vitsupakorn S, Sreerama Reddy K, Brown L, Nguyen TTM, Burke M, Liu J, Evans E, Giamberardino C, Perfect J, Hoa NT, Le T.   +11 more
europepmc   +2 more sources